Show simple item record

dc.contributor.authorCrosbie, Emma J
dc.contributor.authorZwahlen, M
dc.contributor.authorKitchener, Henry C
dc.contributor.authorEgger, M
dc.contributor.authorRenehan, Andrew G
dc.date.accessioned2011-01-21T13:17:34Z
dc.date.available2011-01-21T13:17:34Z
dc.date.issued2010-12
dc.identifier.citationBody mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. 2010, 19 (12):3119-30 Cancer Epidemiol Biomarkers Preven
dc.identifier.issn1538-7755
dc.identifier.pmid21030602
dc.identifier.doi10.1158/1055-9965.EPI-10-0832
dc.identifier.urihttp://hdl.handle.net/10541/120132
dc.description.abstractBody mass index (BMI) is a risk factor for endometrial cancer. We quantified the risk and investigated whether the association differed by use of hormone replacement therapy (HRT), menopausal status, and histologic type.
dc.language.isoenen
dc.subjectBody Mass Indexen
dc.subjectHormone Replacement Therapyen
dc.subjectEndometrial Canceren
dc.titleBody mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis.en
dc.typeArticleen
dc.contributor.departmentGynaecology Oncology Research Group, School of Cancer and Enabling Sciences, University of Manchester, Manchester, UK.en
dc.identifier.journalCancer Epidemiology, Biomarkers & Preventionen
html.description.abstractBody mass index (BMI) is a risk factor for endometrial cancer. We quantified the risk and investigated whether the association differed by use of hormone replacement therapy (HRT), menopausal status, and histologic type.


This item appears in the following Collection(s)

Show simple item record